Intranasal immunization with Chlamydia trachomatis, serovar E, protects from a subsequent vaginal challenge with the homologous serovar

Ellena M. Peterson, John Z. You, Vladimir Motin, Luis M. De La Maza

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

To vaccinate against a vaginal challenge with Chlamydia trachomatis, C3H/HeJ (H-2(k)) mice were immunized intranasally (i.n.) or intraperitoneally (i.p.) with 1 x 106 inclusion forming units (IFU) of C. trachomatis, serovar E and i.n. with 1 x 106 UV inactivated IFU of serovar E. Animals inoculated i.n. with mock infected HeLa 229 cells were used as controls. Upon a vaginal challenge with 5 x 103 IFU of serovar E, mice immunized i.n. with viable serovar E exhibited significant protection as judged by the number of mice infected compared to controls (p < 0.05). In contrast, mice immunized i.n. with serovar E that had been UV-inactivated, were not protected from a subsequent vaginal challenge with serovar E. Mice immunized i.p. with serovar E showed attenuation of the infection by 4 weeks after challenge compared to control mice as to the number of animals with positive vaginal cultures (p < 0.05). Of the immune parameters examined, the best correlation with protection was seen with Chlamydia specific IgG and IgA vaginal titers and lymphoproliferative responses to serovar E. In summary, mucosal immunization with viable serovar E partially protected mice against a subsequent vaginal challenge, thereby showing that it is possible to elicit a protective response to a human strain of C. trachomatis at a distant mucosal site in this animal model.

Original languageEnglish (US)
Pages (from-to)2901-2907
Number of pages7
JournalVaccine
Volume17
Issue number22
DOIs
StatePublished - Jul 16 1999
Externally publishedYes

Fingerprint

Chlamydia trachomatis
Immunization
immunization
serotypes
mice
Serogroup
Chlamydia
HeLa Cells
Immunoglobulin A
animals
Animal Models
Immunoglobulin G
animal models

Keywords

  • Chlamydia trachomatis
  • Genital infection
  • Immunization

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Intranasal immunization with Chlamydia trachomatis, serovar E, protects from a subsequent vaginal challenge with the homologous serovar. / Peterson, Ellena M.; You, John Z.; Motin, Vladimir; De La Maza, Luis M.

In: Vaccine, Vol. 17, No. 22, 16.07.1999, p. 2901-2907.

Research output: Contribution to journalArticle

@article{2096d12ca6b94ae9af441be0c34c379a,
title = "Intranasal immunization with Chlamydia trachomatis, serovar E, protects from a subsequent vaginal challenge with the homologous serovar",
abstract = "To vaccinate against a vaginal challenge with Chlamydia trachomatis, C3H/HeJ (H-2(k)) mice were immunized intranasally (i.n.) or intraperitoneally (i.p.) with 1 x 106 inclusion forming units (IFU) of C. trachomatis, serovar E and i.n. with 1 x 106 UV inactivated IFU of serovar E. Animals inoculated i.n. with mock infected HeLa 229 cells were used as controls. Upon a vaginal challenge with 5 x 103 IFU of serovar E, mice immunized i.n. with viable serovar E exhibited significant protection as judged by the number of mice infected compared to controls (p < 0.05). In contrast, mice immunized i.n. with serovar E that had been UV-inactivated, were not protected from a subsequent vaginal challenge with serovar E. Mice immunized i.p. with serovar E showed attenuation of the infection by 4 weeks after challenge compared to control mice as to the number of animals with positive vaginal cultures (p < 0.05). Of the immune parameters examined, the best correlation with protection was seen with Chlamydia specific IgG and IgA vaginal titers and lymphoproliferative responses to serovar E. In summary, mucosal immunization with viable serovar E partially protected mice against a subsequent vaginal challenge, thereby showing that it is possible to elicit a protective response to a human strain of C. trachomatis at a distant mucosal site in this animal model.",
keywords = "Chlamydia trachomatis, Genital infection, Immunization",
author = "Peterson, {Ellena M.} and You, {John Z.} and Vladimir Motin and {De La Maza}, {Luis M.}",
year = "1999",
month = "7",
day = "16",
doi = "10.1016/S0264-410X(99)00131-0",
language = "English (US)",
volume = "17",
pages = "2901--2907",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "22",

}

TY - JOUR

T1 - Intranasal immunization with Chlamydia trachomatis, serovar E, protects from a subsequent vaginal challenge with the homologous serovar

AU - Peterson, Ellena M.

AU - You, John Z.

AU - Motin, Vladimir

AU - De La Maza, Luis M.

PY - 1999/7/16

Y1 - 1999/7/16

N2 - To vaccinate against a vaginal challenge with Chlamydia trachomatis, C3H/HeJ (H-2(k)) mice were immunized intranasally (i.n.) or intraperitoneally (i.p.) with 1 x 106 inclusion forming units (IFU) of C. trachomatis, serovar E and i.n. with 1 x 106 UV inactivated IFU of serovar E. Animals inoculated i.n. with mock infected HeLa 229 cells were used as controls. Upon a vaginal challenge with 5 x 103 IFU of serovar E, mice immunized i.n. with viable serovar E exhibited significant protection as judged by the number of mice infected compared to controls (p < 0.05). In contrast, mice immunized i.n. with serovar E that had been UV-inactivated, were not protected from a subsequent vaginal challenge with serovar E. Mice immunized i.p. with serovar E showed attenuation of the infection by 4 weeks after challenge compared to control mice as to the number of animals with positive vaginal cultures (p < 0.05). Of the immune parameters examined, the best correlation with protection was seen with Chlamydia specific IgG and IgA vaginal titers and lymphoproliferative responses to serovar E. In summary, mucosal immunization with viable serovar E partially protected mice against a subsequent vaginal challenge, thereby showing that it is possible to elicit a protective response to a human strain of C. trachomatis at a distant mucosal site in this animal model.

AB - To vaccinate against a vaginal challenge with Chlamydia trachomatis, C3H/HeJ (H-2(k)) mice were immunized intranasally (i.n.) or intraperitoneally (i.p.) with 1 x 106 inclusion forming units (IFU) of C. trachomatis, serovar E and i.n. with 1 x 106 UV inactivated IFU of serovar E. Animals inoculated i.n. with mock infected HeLa 229 cells were used as controls. Upon a vaginal challenge with 5 x 103 IFU of serovar E, mice immunized i.n. with viable serovar E exhibited significant protection as judged by the number of mice infected compared to controls (p < 0.05). In contrast, mice immunized i.n. with serovar E that had been UV-inactivated, were not protected from a subsequent vaginal challenge with serovar E. Mice immunized i.p. with serovar E showed attenuation of the infection by 4 weeks after challenge compared to control mice as to the number of animals with positive vaginal cultures (p < 0.05). Of the immune parameters examined, the best correlation with protection was seen with Chlamydia specific IgG and IgA vaginal titers and lymphoproliferative responses to serovar E. In summary, mucosal immunization with viable serovar E partially protected mice against a subsequent vaginal challenge, thereby showing that it is possible to elicit a protective response to a human strain of C. trachomatis at a distant mucosal site in this animal model.

KW - Chlamydia trachomatis

KW - Genital infection

KW - Immunization

UR - http://www.scopus.com/inward/record.url?scp=0033575490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033575490&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(99)00131-0

DO - 10.1016/S0264-410X(99)00131-0

M3 - Article

C2 - 10438062

AN - SCOPUS:0033575490

VL - 17

SP - 2901

EP - 2907

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 22

ER -